Get The Alerts + Report

BridgeBio Pharma, Inc. [BBIO]

Reporting date: 10/08/2025

⚠️ Neutral Insider Sale Detected

📝 What Happened

  • Insider: Kumar Neil
  • Role: Chief Executive Officer (Director)
  • Company: BridgeBio Pharma, Inc. (BBIO)
  • Transaction Date(s): 2025-10-08, 2025-10-09
  • Table I (Non-Derivative Securities)
    • Sale : 80,000 shares
    • Average Sale Price: $54.79
    • Total Value: $4,383,442.21
    • Post-Transaction Direct Holdings: 223,090 shares
    • Indirect Holdings: 5,474,133 shares
    • 10b5-1 Plan Used? Yes (Rule 10b5-1 sales plan)

📄 Summary

Kumar Neil, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 80,000 shares on October 8–9, 2025, at an average price of $54.79, realizing proceeds of about ~$4,383,442. After the transaction, he now holds 223,090 direct shares and 5,474,133 indirect shares. For retail traders, this is a neutral-to-slightly bearish event: routine planned sales by a CEO under a 10b5-1 plan, small relative to total holdings.

🔑 Interpretation

  • Type: Comp-related (transactions effected pursuant to a Rule 10b5-1 sales plan)
  • Disposition: Shares were sold immediately under the 10b5-1 plan (transaction code S, disposed = D)
  • Size Context: The sale of 80,000 shares represents roughly ~1.4% of the reporting person’s combined direct and indirect holdings (~5.70M shares), so this appears to be routine profit-taking rather than a large, discretionary divestiture.
  • ATH Metric: The sales occurred in the ~$53.8–$55.3 range (weighted avg ~$54.79), i.e., near the recent trading range implied by the filing footnotes. This is not clearly at an all-time high or low relative to the company’s full price history and looks opportunistic within a short-term trading window rather than timed to an ATH or LTH.
  • Outlier Check: Not unusually large compared to the holder’s multi-million share position and consistent with a pre-established 10b5-1 plan; not an outlier.

📊 Bullish or Bearish?

Decide: Neutral

Neutral. The filing shows planned sales (10b5-1) by the CEO, representing a small fraction of total holdings and likely routine liquidity rather than a signal of deteriorating insider sentiment; data completeness is good for these transactions but cluster activity cannot be determined from this filing alone.

✅ Bottom Line (Retail Takeaway)

This transaction looks like routine profit-taking rather than a bearish signal. For retail traders, it’s noise, not a tradeable event — not worth short-/mid-term action unless corroborated by sales from the company's CEO, CFO, or multiple insiders.